Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
CINCINNATI--(BUSINESS WIRE)--Jun. 26, 2024-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results.
辛辛那提--(美國商業資訊)--2024年6月26日--Medpace Holdings, Inc.（納斯達克股票代碼：MEDP）（“Medpace”）今天宣佈，它將在2024年7月22日星期一收盤後公佈其2024年第二季度財務業績。該公司將於美國東部時間2024年7月23日星期二上午9點舉行電話會議，討論這些結果。
To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
要參加電話會議，感興趣的各方必須通過點擊提前註冊 這個鏈接。雖然不是必需的，但建議您在活動開始前 10 分鐘加入。註冊後，所有電話參與者都將收到一封確認電子郵件，詳細說明如何加入電話會議，包括撥入號碼以及可用於接聽電話的唯一 PIN。
To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
要通過網絡直播觀看電話會議，請訪問Medpace網站的 “投資者” 部分，網址爲 investor.medpace.com。電話會議結束大約一小時後，電話會議的網絡直播重播將在同一站點上播出。
A supplemental slide presentation will also be available at the "Investors" section of Medpace's website prior to the start of the call.
在電話會議開始之前，還將在Medpace網站的 “投資者” 部分提供補充幻燈片演示。
About Medpace
關於 Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 42 countries as of March 31, 2024.
Medpace是一家以科學爲導向的全球性全方位臨床合同研究組織（CRO），爲生物技術、製藥和醫療器械行業提供I-IV期臨床開發服務。Medpace的使命是通過其高科學和紀律嚴明的運營方法，利用腫瘤、心臟病學、代謝疾病、內分泌學、中樞神經系統以及抗病毒和抗感染等所有主要領域的監管和治療專業知識，加速安全有效的醫療療法的全球開發。Medpace總部位於俄亥俄州辛辛那提，截至2024年3月31日，在42個國家擁有約5,800名員工。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626082979/en/
Investor Contact:
Lauren Morris
513.579.9911 x11994
l.morris@medpace.com
投資者聯繫人：
勞倫莫里斯
513.579.9911 x11994
l.morris@medpace.com
Media Contact:
Julie Hopkins
513.579.9911 x12627
j.hopkins@medpace.com
媒體聯繫人：
朱莉霍普金
513.579.9911 x12627
j.hopkins@medpace.com
Source: Medpace Holdings, Inc.
資料來源：Medpace Holdings, Inc.
譯文內容由第三人軟體翻譯。